Migraine prophylactic drugs: Proof of efficacy, utilization and cost

Cephalalgia

Volumn 17, Issue 2, 1997, Pages 73-80

  Ramadan, N M ^a   Schultz, L L ^b   Gilkey, S J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

Author keywords

Clinical trials; Drug therapy; Headache; Migraine; Utilization

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ALPRENOLOL; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONIDINE; DIHYDROERGOTAMINE; FLUOXETINE; FLURBIPROFEN; METHYSERGIDE; METOPROLOL; NADOLOL; NAPROXEN; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PINDOLOL; PIZOTIFEN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TIMOLOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG UTILIZATION; HUMAN; MEDICAL INFORMATION; MEDICAL SPECIALIST; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIMARY MEDICAL CARE; PROPHYLAXIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADULT; AMITRIPTYLINE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PROPRANOLOL; VERAPAMIL;

EID: 0030908941     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1702073.x     Document Type: Review

References (101)

1. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995;15:45-68
2. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994;44 Suppl 4:S24-S39
3. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 1996;16:231-8
4. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York: Raven Press, 1993:299-303
5. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991;11:1-12
6. Adelman JU, Von Seggern R. Cost considerations in headache treatment part 1: prophylactic migraine treatment. Headache 1995;35:479-87
7. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology 1972;22:366-9
8. Malvea BP, Gwon N, Graham JR. Propranolol prophylaxis of migraine. Headache 1973;13:163-7
9. Widerøe TE, Vigander T. Propranolol in the treatment of migraine. Br Med J 1974;2:699-701
10. Børgesen SE, Nielsen JL, Møller CE. Prophylactic treatment of migraine with propranolol. A clinical trial. Acta Neurol Scand 1974;50:651-6
11. Forssman B, Henriksson KG, Johannsson V, Lindvall L, Lundin H. Propranolol for migraine prophylaxis. Headache 1976;16:238-45
12. Stensrud P, Sjaastad O. Short-term clinical trial of propranolol in racemic form (Inderal), d-propranolol and placebo in migraine. Acta Neurol Scand 1976;53:229-32
13. Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 1980;20:204-7
14. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 1986;73:490-92
15. Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. Headache 1982;22:268-71
16. Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia 1982;2:165-70
17. Ahuja GK, Verma AK. Propranolol in prophylaxis of migraine. Indian J Med Res 1985;82:263-5
18. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985; 25:320-4
19. Mikkelsen B, Kjærsgaard Pedersen K, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand 1986;73:423-7
20. Nadelmann JW, Phil M, Stevens J, Saper JR. Propranolol in the prophylaxis of migraine. Headache 1986;26:175-82
21. Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo (abstract). Cephalalgia 1987;7:457-8
22. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-9
23. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo controlled study. Cephalalgia 1989;9:247-53
24. Al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia 1993;13:128-31
25. Anderson PG, Dahl S, Hansen PE, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol - a comparison with placebo. Cephalalgia 1983;3:207-12
26. Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987;7:231-8
27. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache 1988;28:15-23
28. Nanda RN, Johnson RH, Gray J, Keogh HJ, Melville ID. A double blind trial of acebutolol for migraine prophylaxis. Headache 1978;18:20-2
29. Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy) indol an adrenergic beta-receptor blocking agent in migraine prophylaxis. Headache 1972;12:15-7
30. Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. Acta Neurol Scand 1972;48:124-8
31. Ekbom K, Zetterman M. Oxprenolol in the treatment of migraine. Acta Neurol Scand 1977;56:181-4
32. Ekbom K. Alprenolol for migraine prophylaxis. Headache 1975;15:129-32
33. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983;23:188-90
34. Johannsson V, Nilsson LR, Widelius T, et al. Atenolol in migraine prophylaxis: a double-blind cross-over multicentre study. Headache 1987;27:372-4
35. Briggs RS, Millac PA. Timolol in migraine prophylaxis. Headache 1979;19:379-81
36. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA 1984;252:2576-80
37. Ryan RE, Ryan RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 1983;23:26-31
38. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973;36:684-90
39. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9
40. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-9
41. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32:101-4
42. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502
43. Lindegaard KF, Övrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache 1980;20:96-8
44. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304-10
45. Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985;42:582-4
46. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990;30:710-15
47. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990;30:705-9
48. O'Neill BP, Mann JD. Aspirin prophylaxis in migraine. Lancet 1978;ii:1179-81
49. Hosman-Benjaminse SL, Bolhuis PA. Migraine and platelet aggregation in patients treated with low dose acetylsalicylic acid. Headache 1986;26:282-4
50. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-3
51. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo. Acta Neurol Scand 1982;66:105-11
52. Carrieri PB, Orefice G, Sorge F. A double-blind placebo-controlled trial of indobufen in the prophylaxis of migraine. Acta Neurol Scand 1988;77:433-6
53. Solomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. Cleve Clin J Med 1993;60:43-8
54. Diamond S, Solomon GD, Freitag FG, Mehta ND. Fenoprofen in the prophylaxis of migraine: a double-blind, placebo-controlled study. Headache 1987;27:246-9
55. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 R.P.) in migraine prophylaxis. Headache 1974;14:96-100
56. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo controlled study. JAMA 1983;250:2500-2
57. Markley HG, Cheronis JCD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973-6
58. Solomon GD, Diamond S, Freitag FG. Verapamil in migraine prophylaxis comparison of dosages (abstract). Clin Pharmacol Ther 1987;41:202
59. Solomon GD. Verapamil and propranolol in migraine prophylaxis: a double-blind, crossover study (abstract). Headache 1986;26:325
60. Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 1983;23:106-9
61. Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia 1985;5:39-43
62. Ansell E, Fazzone T, Festenstein R, Johnson ES, Thavapalan M, Wilkinson M, Wozniak I. Nimodipine in migraine prophylaxis. Cephalalgia 1988;8:269-72
63. Stewart DJ, Gelston A, Hakim A. Effect of prophylactic administration of nimodipine in patients with migraine. Headache 1988;28:260-2
64. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 1989;29:633-8
65. Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 1989;29:639-42
66. Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986;6:7-14
67. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium®) in migraine. Headache 1981; 21:235-9
68. Frenken CWGM, Nuijten STM. Flunarizine, a new preventative approach to migraine. A double-blind comparison with placebo. Clin Neurol Neurosurg 1984;86:17-20
69. Mendenopoulos G, Manafi Th, Logothetis I, Bostantjopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985;5:31-7
70. Diamond S, Freitag FG. A double blind trial of flunarizine in migraine prophylaxis. In: Clifford Rose F, editor. New advances in headache research: 2. London. Smith-Gordon, 1991:349-54
71. Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache 1991;31:613-5
72. Kahan A, Weber S, Amor B, Guerin F, Degeorges M. Nifedipine in the treatment of migraine in patients with Raynaud's phenomenon (abstract). N Engl J Med 1983;308:1102-3
73. McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989;39:284-6
74. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. SA Med J 1970;44:75-80
75. Welch KMA, Chabi E, Bartosh K, Achar VS, Meyer JS. Cerebrospinal fluid gamma-aminobutyric acid levels in migraine. Br Med J 1975;3:516-7
76. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4
77. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-51
78. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
79. Klapper J. (on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group). Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997:17 (in press)
80. Southwell N, Williams JD, Mackenzie I. Methysergide in the prophylaxis of migraine. Lancet 1964;1:523-4
81. Pedersen E, Møller CE. Methysergide in migraine prophylaxis. Clin Pharmacol Ther 1966;7:520-6
82. Ryan RE. Double-blind crossover comparison of BC-105, methysergide and placebo in the prophylaxis of migraine headache. Headache 1968;8:118-26
83. Lance JW, Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust 1968;6:54-5
84. Sjaastad O, Stensrud P. Appraisal of BC-105 in migraine prophylaxis. Acta Neurol Scand 1969;45:594-600
85. Arthur GP, Hornabrook RW. The treatment of migraine with BC 105 (pizotifen): a double blind trial. NZ Med J 1971;73:5-9
86. Hughes RC, Foster JB. BC 105 in the prophylaxis of migraine. Curr Ther Res 1971;13:63-8
87. Ryan RE. BC-105 a new preparation for the interval treatment of migraine - a double blind evaluation compared with a placebo. Headache 1971;11:6-18
88. Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Op 1975;3:68-71
89. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis; controlled multicenter trial in general practice. Headache 1977;17:109-12
90. Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan®) in migraine prophylaxis. Acta Neurol Scand 1977;56:17-28
91. Sjaastad O, Stensrud P. 2-(2.6-Dichlorophenylamino)-2-imidazoline hydrochloride (ST 155 or Catapresan) as a prophylactic remedy against migraine. Acta Neurol Scand 1971;47:120-2
92. Shafar J, Tallett ER. Evaluation of clonidine in prophylaxis of migraine. Lancet 1972;1:403-10
93. Ryan RE, Diamond S, Ryan RE. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. Headache 1975;15:202-6
94. Kallanranta T, Hakkarainen H, Hokkanen E, Tuovinen T. Clonidine in migraine prophylaxis. Headache 1977;17:169-72
95. Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. Acta Neurol Scand 1979;60:214-7
96. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. J Fam Pract 1989;29:153-8
97. Martucci N, Manna V, Mattesi P, et al. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation. Cephalalgia 1983;3 Suppl 1:150-5
98. Neuman M, Demarez JP, Harmey JL, Le Bastard B, Cauquil J. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharm Res 1986;1:11-3
99. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
100. Spitzer WO. editor. The Postdam International Consultation on Meta-analysis. J Clin Epidemiol 1995;48:1-171
101. Moher D, Olkin I. Meta-analysis of randomized controlled trials. A concern for standards. JAMA 1995;274:1962-4